Spyre Therapeutics Q2 EPS $(0.36) Beats $(0.73) Estimate
Spyre Therapeutics (NASDAQ:SYRE) reported quarterly losses of $(0.36) per share which beat the analyst consensus estimate of $(0.73) by 50.68 percent. This is a 26.53 percent increase over losses of $(0.49) per share
Spyre lost less money than experts thought it would—a good sign for a company still spending money to grow. When a company loses less than people expected, it shows its business plans might be working better than feared.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.